ADALIMUMAB

adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices

ADALIMUMAB (12362P)

adalimumab 40 mg/0.4 mL injection, 2 x 0.4 mL pen devices
12362P
Body System:
Manner of administration:Injection
General Schedule
Authority Required

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)

Restriction

Indication: Severe psoriatic arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 2 # of repeats: 3 DPMQ: $494.12 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Hadlima
Humira
Hyrimoz
Yuflyma